EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Improved Clinical Outcomes With Elexacaftor/Tezacaftor/Ivacaftor in Patients With Cystic Fibrosis and Advanced Lung Disease: Real‐World Evidence From an Italian Single‐Center Study

Nicola Perrotta iD, Luigi Angelo Fiorito, Gianfranco Casini, Rossella Gentile, Roberta Vescovo, Alfonso Piciocchi, Roberta Lobello, Carlo Cappelli, Roberto Poscia, Giuseppe Cimino

Pharmacology Research & Perspectives · 2025

DOI: 10.1002/prp2.70083 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmacology Research & Perspectives, 2025. Verfasst von Nicola Perrotta und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Physiology and Pharmacology "V. Erspamer", Sapienza University, Rome, Italy. Hauptthemen laut MEDLINE: Cystic Fibrosis, Aminophenols, Quinolones, Benzodioxoles. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The combination of Elexacaftor/Tezacaftor/Ivacaftor (ETI) has resulted in a significant improvement in lung function and global clinical parameters, which have not been previously achieved with other CFTR modulators. However, there is a paucity of evidence in the literature on the long‐term use of ETI in adolescents and patients with severe pulmonary impairment. Furthermore, the response to ETI may differ between homozygotes and heterozygotes, as well as between naïve patients and those previously treated with other CFTR modulators. A retrospective study was conducted to examine changes in percent predicted forced expiratory volume in 1 s (ppFEV 1 ), body‐mass index (BMI), and sweat chloride concentration (SwCl) at baseline and at 6, 12 and 24 months after the initiation of ETI. Secondary outcomes included the number of pulmonary exacerbations, Cystic Fibrosis Questionnaire‐Revised (CFQ‐R) score, adverse events, mortality and transplantation rates. 139 subjects were included and followed up for up to 2 years after starting ETI. The results demonstrated a significant improvement in ppFEV 1 and BMI after 12 months of therapy (respectively, 16%, p < 0.001; +1.5 kg/m 2 , p = 0.005), with a slight decline in the values after 24 months. This effect was independent of genotype and showed a different degree of response in naïve subjects compared to patients previously treated with other CFTR modulators. SwCl decreased from 84 to 37 mmol/L over 24 months ( p < 0.001). 58.3% reduction of PEx rate was observed compared to the number of exacerbations prior to ETI. Overall, lung function, SwCl, PEx rate, CFQ‐R scores and BMI improved after 24 months of ETI treatment. ETI was well tolerated, and none of the patients interrupted the treatment due to toxicity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cystic FibrosisAminophenolsQuinolonesBenzodioxolesIndolesPyrazolesChloride Channel AgonistsPyridinesPyrrolidinesHumansMaleFemaleRetrospective StudiesAdolescentDrug CombinationsAdultCystic Fibrosis Transmembrane Conductance RegulatorYoung AdultTreatment OutcomeItalyForced Expiratory VolumeBody Mass IndexSweatChildQuinolines

Stichwörter der Autor:innen

CFTRElexacaftor‐Tezacaftor‐Ivacaftorcystic fibrosiseffectivenesssafety

Substanzen

AminophenolsQuinolonesDrug CombinationsBenzodioxolesIndolesCystic Fibrosis Transmembrane Conductance RegulatorPyrazolesivacaftorChloride Channel AgonistsPyridines

Autor:innen und Institutionen

  • Department of Physiology and Pharmacology "V. Erspamer", Sapienza University, Rome, Italy.
  • Pharmacy Unit, AOU Policlinico Umberto I-Sapienza University, Rome, Italy.
  • Biostatistics Unit, GIMEMA Foundation, Rome, Italy.
  • Cystic Fibrosis Center, AOU Policlinico Umberto I-Sapienza University, Rome, Italy.
  • Clinical Research Unit, AOU Policlinico Umberto I- Sapienza University, Rome, Italy.
  • Interdepartmental Center for Rare Diseases, AOU Policlinico Umberto I- Sapienza University, Rome, Italy.

ORCID-Profile: Nicola Perrotta

Zitieren

APA

Perrotta, N., Fiorito, L. A., Casini, G., Gentile, R., Vescovo, R., Piciocchi, A., Lobello, R., Cappelli, C., Poscia, R., & Cimino, G. (2025). Improved Clinical Outcomes With Elexacaftor/Tezacaftor/Ivacaftor in Patients With Cystic Fibrosis and Advanced Lung Disease: Real‐World Evidence From an Italian Single‐Center Study. Pharmacology Research & Perspectives. https://doi.org/10.1002/prp2.70083

Vancouver

Perrotta N, Fiorito LA, Casini G, Gentile R, Vescovo R, Piciocchi A, et al. Improved Clinical Outcomes With Elexacaftor/Tezacaftor/Ivacaftor in Patients With Cystic Fibrosis and Advanced Lung Disease: Real‐World Evidence From an Italian Single‐Center Study. Pharmacology Research & Perspectives. 2025. doi:10.1002/prp2.70083

BibTeX
@article{Perrotta2025,
  author = {Perrotta, Nicola and Fiorito, Luigi Angelo and Casini, Gianfranco and Gentile, Rossella and Vescovo, Roberta and Piciocchi, Alfonso and Lobello, Roberta and Cappelli, Carlo and Poscia, Roberto and Cimino, Giuseppe},
  title = {Improved Clinical Outcomes With Elexacaftor/Tezacaftor/Ivacaftor in Patients With Cystic Fibrosis and Advanced Lung Disease: Real‐World Evidence From an Italian Single‐Center Study},
  journal = {Pharmacology Research & Perspectives},
  year = {2025},
  doi = {10.1002/prp2.70083}
}
Kostenlos starten →